Subconjunctival Bevacizumab and Recurrent Pterygium (BRP)

Instituto de Olhos de Goiania

Status and phase: Completed; Phase 3; Phase 2

Conditions: Recurrent Pterygium

Treatments: Drug: Bevacizumab

Study type: Interventional

Funder types: Other

Identifiers

NCT01744756

pterygium bevacizumab

Details and patient eligibility

About

A study to research whether subconjunctival bevacizumab injection may potentially suppress neovascularization in pterygium, retarding and decreasing the size of recurrent pterygium.

Full description

1. Pacients with recurrent pterygium
2. Anti-VEGF therapy -Bevacizumab

Enrollment: 36 patients

Sex: All

Ages: 40 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Recurrent pterygium

Exclusion criteria

• Pregnant or lactating women
• History of myocardial infarction
• History of stroke

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

36 participants in 1 patient group

Subconjunctival Bevacizumab

Experimental group

Description:

One aplication of subconjunctival Bevacizumab 0,5 ml

Treatment:

Drug: Bevacizumab